The reiteration of an Overweight rating by a reputable analyst like Cantor Fitzgerald is a positive signal for Affimed. The maintained price target of $7 also indicates the analyst's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.